Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P. Virgolini I, et al. Among authors: li sr. Nucl Med Biol. 1996 Aug;23(6):685-92. doi: 10.1016/0969-8051(96)00066-2. Nucl Med Biol. 1996. PMID: 8940711
New trends in peptide receptor radioligands.
Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. Virgolini I, et al. Among authors: li sr. Q J Nucl Med. 2001 Jun;45(2):153-9. Q J Nucl Med. 2001. PMID: 11476164 Review.
111In-DOTA- dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study.
Li S, Kurtaran A, Li M, Traub-Weidinger T, Kienast O, Schima W, Angelberger P, Virgolini I, Raderer M, Dudczak R. Li S, et al. Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1087-95. doi: 10.1007/s00259-003-1206-1. Epub 2003 May 24. Eur J Nucl Med Mol Imaging. 2003. PMID: 12768334 Clinical Trial.
Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.
Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, Dudczak R, Virgolini I. Rodrigues M, et al. Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1144-51. doi: 10.1007/s00259-005-1820-1. Epub 2005 May 21. Eur J Nucl Med Mol Imaging. 2005. PMID: 15909194 Clinical Trial.
409 results